Understanding and Controlling the Formation of an Impurity during the Development of Muraglitazar, a PPAR Dual Agonist-Reference-Cited by-同舟云学术

Understanding and Controlling the Formation of an Impurity during the Development of Muraglitazar, a PPAR Dual Agonist

Published:2009-12-08 Issue:1 Volume:14 Page:238-241
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Ye Qingmei¹,Huang Yande¹,Rusowicz Andrew¹,Palaniswamy Venkatapuram A.¹,Raglione Thomas V.¹

Affiliation:

1. Analytical Research and Development and Process Research and Development, Bristol-Myers Squibb Pharmaceutical Company, New Brunswick, New Jersey 08903-0191, U.S.A.

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/op9002104

Reference11 articles.

1. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review

2. Pioglitazone

3. (3-Substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

4. Tesaglitazar

5. Farglitazar

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrasound-assisted efficient synthesis of 3-[4-(2-methoxyethyl) phenoxy] propane -1,2 -diol (Metoprolol EP impurity D);Organic Communications;2021-03-26

2. Multi-column ultra-high performance liquid chromatography screening with chaotropic agents and computer-assisted separation modeling enables process development of new drug substances;The Analyst;2019

3. Preparation, Crystal Structures and Hirshfeld Surface Analyses of Two Impurities of Azilsartan;Journal of Chemical Crystallography;2018-12-03

4. Quality by Design (QbD) and the Development and Manufacture of Drug Substance;Pharmaceutical Quality by Design;2018-01-26

5. Multitargeted bioactive ligands for PPARs discovered in the last decade;Chemical Biology & Drug Design;2016-07-21